{"id":1017966,"date":"2026-11-05T20:43:55","date_gmt":"2026-11-06T01:43:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/"},"modified":"2026-11-05T20:43:55","modified_gmt":"2026-11-06T01:43:55","slug":"larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/","title":{"rendered":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BALA CYNWYD, Pa., Nov.  05, 2026  (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich\u2019s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10\u201313, 2026, in Atlanta, Georgia.<\/p>\n<p align=\"justify\">\n        <strong>Poster Presentation Details<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Abstract Title:<\/strong> Long-Term Daily Nomlabofusp Administration in Patients with Friedreich\u2019s Ataxia: Interim Observations from an Ongoing Open-Label Study<\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>Abstract Title:<\/strong> Plasma Lipid Profiles in Patients with Friedreich\u2019s Ataxia Before and After Treatment with Nomlabofusp<\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>Abstract Title:<\/strong> Dysregulated Gene Expression in Friedreich\u2019s Ataxia and Response to Treatment with Nomlabofusp<\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">All three posters will be presented during the <em>Poster Session Day 3<\/em> on Thursday, November 12, from 6:30 to 7:30 p.m. ET in the Poster and Exhibitor Hall (D) at the Cobb Convention Center.<\/p>\n<p align=\"justify\">\n        <strong>About Larimar Therapeutics<\/strong><br \/>\n        <br \/>Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich&#8217;s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=COXLD5IVKkBn-ilyM8qwukFZU6P0ocaUrhyyUh5NEp6PuXv1K9h-VyvtG1cWa93LMGfNxSbxtH1pH2TOJtnxEvK6O7PRVIZmz4DYcHfKrtk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/larimartx.com<\/a>.<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Investor Contact:<\/strong><br \/>\n            <br \/>Joyce Allaire\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>LifeSci Advisors\u00a0<br \/><a href=\"mailto:jallaire@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a>\u00a0\u00a0 \u00a0\u00a0<br \/>(212) 915-2569<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Company Contact:<\/strong><br \/>\n            <br \/>Michael Celano\u00a0<br \/>Chief Financial Officer<br \/><a href=\"mailto:mcelano@larimartx.com\" rel=\"nofollow\" target=\"_blank\">mcelano@larimartx.com<\/a><br \/>(484) 414-2715<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGMxNTdmNWQtZGZkNi00OTllLThkMDMtMWVlNDkxYzExNDVjLTUwMDA3Nzg4OS0yMDI2LTExLTA1LWVu\/tiny\/Larimar-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich\u2019s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10\u201313, 2026, in Atlanta, Georgia. Poster Presentation Details Abstract Title: Long-Term Daily Nomlabofusp Administration in Patients with Friedreich\u2019s Ataxia: Interim Observations from an Ongoing Open-Label Study Abstract Title: Plasma Lipid Profiles in Patients with Friedreich\u2019s Ataxia Before and After &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017966","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich\u2019s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10\u201313, 2026, in Atlanta, Georgia. Poster Presentation Details Abstract Title: Long-Term Daily Nomlabofusp Administration in Patients with Friedreich\u2019s Ataxia: Interim Observations from an Ongoing Open-Label Study Abstract Title: Plasma Lipid Profiles in Patients with Friedreich\u2019s Ataxia Before and After &hellip; Continue reading &quot;Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T01:43:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research\",\"datePublished\":\"2026-11-06T01:43:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/\"},\"wordCount\":278,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/\",\"name\":\"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2026-11-06T01:43:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk","og_description":"BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich\u2019s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10\u201313, 2026, in Atlanta, Georgia. Poster Presentation Details Abstract Title: Long-Term Daily Nomlabofusp Administration in Patients with Friedreich\u2019s Ataxia: Interim Observations from an Ongoing Open-Label Study Abstract Title: Plasma Lipid Profiles in Patients with Friedreich\u2019s Ataxia Before and After &hellip; Continue reading \"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T01:43:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research","datePublished":"2026-11-06T01:43:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/"},"wordCount":278,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/","name":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==","datePublished":"2026-11-06T01:43:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTU5MyM3OTQ4ODY2IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-three-poster-presentations-for-the-nomlabofusp-program-at-the-upcoming-international-congress-for-ataxia-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017966"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017966\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}